GAO study

Not later than 2 years after the date of enactment of this Act, the Comptroller General of the United States shall— (1) complete a study that assesses the impact of section 727 of the Employee Retirement Income Security Act of 1974, as added by section 2(a), on the out-of-pocket costs associated with oral and patient-administered anticancer medications furnished or dispensed to individuals enrolled in a group health plan to which such section 727 applies, in comparison to individuals enrolled in group health plans or health insurance coverage to which section 727 does not apply, including any recommendations or matters for congressional consideration regarding actions Federal agencies or Congress can take to reduce financial barriers to access to oral and patient-administered anticancer medications; and (2) submit to Congress a report on the results of such study, including recommendations or matters for congressional consideration to improve access to oral and patient-administered anticancer medications for individuals enrolled in group health plans and group or individual health insurance coverage offered by a health insurance issuer.